RAS(ON) multi inhibitor
Phase 2Small molecule
Revolution MedicinesRAS(ON) multi inhibitor is a small molecule that works as a RAS(ON) Inhibitor.[1] It is being investigated across 2 indications, with its most advanced program in Phase 2.
RAS(ON) multi inhibitor is one of 60 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.
2
Indications
0
Total Trials
0
Active Trials
59
Competitors
Pipeline
Status by Indication[2]
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Lenvima
EisaiPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for RAS(ON) multi inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Mechanism of Action
- RAS(ON) Inhibitor[1]
- Modality
- Small molecule[1]
- Highest Phase
- Phase 2
- Company